| [1] |
Wallis AB, Saftlas AF, Hsia J, et al. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens, 2008, 21(5)：521-526.
|
| [2] |
El-Toukhy T, Sunkara S, Khalaf Y. Local endometrial injury and IVF outcome: a systematic review and meta-analysis. Reprod Biomed Online, 2012, 25(4)：345-354.
|
| [3] |
Zhou J, Zhao X, Wang Z, et al. High circulating CD3＋CD56＋CD16＋ natural killer-like T cell levels predict a better IVF treatment outcome. J Reprod Immunol, 2013, 97(2)：197-203.
|
| [4] |
Hu X, Liu G, Hou Y, et al. Induction of M2-like macrophages in recipient NOD-scid mice by allogeneic donor CD4(＋)CD25(＋) regulatory T cells. Cell Mol Immunol, 2012, 9(6)：464-472.
|
| [5] |
Koga K, Aldo PB, Mor G. Toll-like receptors and pregnancy: trophoblast as modulators of the immune response. J Obstet Gynaecol Res, 2009, 35(2)：191-202.
|
| [6] |
Cerdeira AS, Kopcow HD, Karumanchi SA. Regulatory T cells in preeclampsia: some answers, more questions？. Am J Pathol, 2012, 181(6)：1900-1902.
|
| [7] |
Schumacher A, Heinze K, Witte J, et al. Human chorionic gonadotropin as a central regulator of pregnancy immune tolerance. J Immunol, 2013, 190(6)：2650-2658.
|
| [8] |
Zhou J, Wang Z, Zhao X, et al. An increase of Treg cells in the peripheral blood is associated with a better in vitro fertilization treatment outcome. Am J Reprod Immunol, 2012, 68(2)：100-106.
|
| [9] |
Varghese S, Crocker I, Bruce IN, et al. Systemic lupus erythematosus, regulatory T cells and pregnancy. Expert Rev Clin Immunol, 2011, 7(5)：635-648.
|
| [10] |
Jianjun Z, Yali H, Zhiqun W, et al. Imbalance of T-cell transcription factors contributes to the Th1 type immunity predominant in pre-eclampsia. Am J Reprod Immunol, 2010, 63(1)：38-45.
|
| [11] |
Lao TT, Sahota DS, Cheng YK, et al. Maternal hepatitis B surface antigen status and incidence of pre-eclampsia. J Viral Hepat, 2013, 20(5)：343-349.
|
| [12] |
Warner JA, Zwezdaryk KJ, Day B, et al. Human cytomegalovirus infection inhibits CXCL12- mediated migration and invasion of human extravillous cytotrophoblasts. Virol J, 2012, 9：255.
|
| [13] |
Franceschi F, Di Simone N, D′Ippolito S, et al. Antibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia？. Helicobacter, 2012, 17(6)：426-434.
|
| [14] |
Chen Y, Huang Y, Jiang R, et al. Syncytiotrophoblast-derived microparticle shedding in early-onset and late-onset severe pre-eclampsia. Int J Gynaecol Obstet, 2012, 119(3)：234-238.
|
| [15] |
Messerli M, May K, Hansson SR, et al. Feto-maternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta, 2010, 31(2)：106-112.
|
| [16] |
Kshirsagar SK, Alam SM, Jasti S, et al, Immunomodulatory molecules are released from the first trimester and term placenta via exosomes. Placenta, 2012, 33(12)：982-990.
|
| [17] |
Redman CW, Tannetta DS, Dragovic RA, et al. Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta, 2012, 33 Suppl：S48-S54.
|
| [18] |
Luo SS, Ishibashi O, Ishikawa G, et al. Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. Biol Reprod, 2009, 81(4)：717-279.
|
| [19] |
Atay S, Gercel-Taylor C, Taylor DD. Human trophoblast-derived exosomal fibronectin induces pro-inflammatory IL-1β production by macrophages. Am J Reprod Immunol, 2011, 66(4)：259-269.
|
| [20] |
Chatterjee P, Weaver LE, Doersch KM, et al. Placental Toll-like receptor 3 and Toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. PLoS One, 2012, 7(7)：e41884.
|
| [21] |
Pineda A, Verdin-Terán SL, Camacho A, et al. Expression of toll-like receptor TLR-2, TLR-3, TLR-4 and TLR-9 is increased in placentas from patients with preeclampsia. Arch Med Res, 2011, 42(5)：382-391.
|
| [22] |
Dai Y, Qiu Z, Diao Z, et al. MicroRNA-155 inhibits proliferation and migration of human extravillous trophoblast derived HTR-8/SVneo cells via down-regulating cyclin D1. Placenta, 2012, 33(10)：824-829.
|
| [23] |
Zhang Y, Diao Z, Su L, et al. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am J Obstet Gynecol, 2010, 202(5)：466.e1-e7.
|
| [24] |
Dai Y, Diao Z, Sun H, et al. MicroRNA-155 is involved in the remodelling of human-trophoblast-derived HTR-8/SVneo cells induced by lipopolysaccharides. Hum Reprod, 2011, 26(7)：1882-1891.
|
| [25] |
Zhang X, Ding L, Diao Z, et al. CYR61 modulates the vascular endothelial growth factor C expression of decidual NK cells via PI3K/AKT pathway. Am J Reprod Immunol, 2012, 67(3)：216-223.
|
| [26] |
Xue P, Zheng M, Diao Z, et al. miR-155* mediates suppressive effect of PTEN 3′-untranslated region on AP-1/NF-κB pathway in HTR-8/SVneo cells. Placenta, 2013, 34(8)：650-656.
|
| [27] |
Sun HX, Zeng DY, Li RT, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension, 2012, 60(6)：1407-1414.
|
| [28] |
Vadnais MA, Rana S, Quant HS, et al., The impact of magnesium sulfate therapy on angiogenic factors in preeclampsia. Pregnancy Hypertens, 2012, 2(1)：16-21.
|
| [29] |
Thangaratinam S, Rogozinska E, Jolly K, et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ, 2012, 344：e2088.
|
| [30] |
Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA, 2013, 309(11)：1154-1162.
|